Aspira Women's HealthAWH
About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Employees: 64
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.19% more ownership
Funds ownership: 11.23% [Q2] → 12.42% (+1.19%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
19% less funds holding
Funds holding: 26 [Q2] → 21 (-5) [Q3]
22% less capital invested
Capital invested by funds: $2.08M [Q2] → $1.62M (-$467K) [Q3]
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for AWH.
Financial journalist opinion
Based on 4 articles about AWH published over the past 30 days
